PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bosentan→

Bosentan PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
147536-97-8
Molecular formula
C27H29N5O6S
Molecular weight
551.6 g/mol
Drug class
Dual endothelin receptor antagonist (ERA)vasodilator for pulmonary arterial hypertension
Mechanism of action
Competitively antagonises endothelin ETA and ETB receptors. This reduces endothelin-mediated vasoconstriction and proliferative effects in pulmonary vascular smooth muscle, lowering pulmonary vascular resistance.
Indications / reported uses
  • Treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and reduce clinical worsening in eligible adults and paediatric patients; current age, functional-class and monitoring criteria are product-label specific

Sources: US DailyMed — Bosentan tablets, updated June 2 2026 · EMA EPAR — Tracleer · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Bosentan PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bosentan Permitted Daily Exposure (PDE) report (the Bosentan PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bosentan Occupational Exposure Limit (OEL) report (the Bosentan OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.